📊 SYRE Key Takeaways
Is Spyre Therapeutics, Inc. (SYRE) a Good Investment?
Spyre Therapeutics is a pre-revenue biotech company facing critical funding runway of approximately 6 months, with annual operating cash burn of $169.3M against $85.7M in liquid assets. While the company maintains a debt-free balance sheet with $777.8M in total assets, the severe cash burn rate relative to remaining capital, combined with zero revenue generation, creates imminent execution risk requiring either significant capital raises, substantial burn reduction, or near-term regulatory/clinical success.
Why Buy Spyre Therapeutics, Inc. Stock? SYRE Key Strengths
- Zero debt burden with clean balance sheet (Debt/Equity: 0.00x)
- Substantial asset base of $777.8M provides strategic flexibility
- Excellent liquidity position with 13.25x current ratio
SYRE Stock Risks: Spyre Therapeutics, Inc. Investment Risks
- Critical cash runway of approximately 6 months at current burn rate
- Extreme cash burn of $169.3M annually with zero revenue offsetting losses
- Complete dependence on capital markets access or clinical milestone achievement for survival
Key Metrics to Watch
- Quarterly operating cash burn rate and cash position trends
- Clinical trial progress and regulatory filing timeline for lead candidates
- Capital raise announcements and debt facility changes
Spyre Therapeutics, Inc. (SYRE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 13.25x current ratio provides a solid financial cushion.
SYRE Profit Margin, ROE & Profitability Analysis
SYRE vs Healthcare Sector: How Spyre Therapeutics, Inc. Compares
How Spyre Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Spyre Therapeutics, Inc. Stock Overvalued? SYRE Valuation Analysis 2026
Based on fundamental analysis, Spyre Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Spyre Therapeutics, Inc. Balance Sheet: SYRE Debt, Cash & Liquidity
SYRE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Spyre Therapeutics, Inc.'s revenue has declined by 95% over the 5-year period, indicating business contraction. The most recent EPS of $-25.02 indicates the company is currently unprofitable.
SYRE Revenue Growth, EPS Growth & YoY Performance
SYRE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | N/A | -$18.4M | $-1.36 |
| Q2 2024 | N/A | -$18.4M | $-0.86 |
| Q1 2024 | N/A | -$18.4M | $-1.20 |
| Q3 2023 | N/A | -$18.2M | $-4.84 |
| Q2 2023 | $625.0K | -$18.4M | $-0.27 |
| Q1 2023 | $198.0K | -$18.4M | $-0.20 |
| Q3 2022 | $174.0K | -$6.8M | $-0.19 |
| Q2 2022 | $625.0K | -$6.8M | $-0.10 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Spyre Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
SYRE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Spyre Therapeutics, Inc. (CIK: 0001636282)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SYRE
What is the AI rating for SYRE?
Spyre Therapeutics, Inc. (SYRE) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SYRE's key strengths?
Claude: Zero debt burden with clean balance sheet (Debt/Equity: 0.00x). Substantial asset base of $777.8M provides strategic flexibility.
What are the risks of investing in SYRE?
Claude: Critical cash runway of approximately 6 months at current burn rate. Extreme cash burn of $169.3M annually with zero revenue offsetting losses.
What is SYRE's revenue and growth?
Spyre Therapeutics, Inc. reported revenue of $0.0.
Does SYRE pay dividends?
Spyre Therapeutics, Inc. does not currently pay dividends.
Where can I find SYRE SEC filings?
Official SEC filings for Spyre Therapeutics, Inc. (CIK: 0001636282) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SYRE's EPS?
Spyre Therapeutics, Inc. has a diluted EPS of $-1.24.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SYRE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Spyre Therapeutics, Inc. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SYRE stock overvalued or undervalued?
Valuation metrics for SYRE: ROE of -21.7% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SYRE stock in 2026?
Our dual AI analysis gives Spyre Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SYRE's free cash flow?
Spyre Therapeutics, Inc.'s operating cash flow is $-169.3M, with capital expenditures of $0.0.
How does SYRE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -21.7% (avg: 15%), current ratio 13.25 (avg: 2).